Willy A J Poppe

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

H. Kitchener, M. Lehtinen, X. Castellsagué, 2012, The Lancet. Oncology.

Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human Papillomavirus Type 16/18 Antibodies: Analysis of the Control Arm of PATRICIA

C. Wheeler, H. Kitchener, M. Lehtinen, 2014, The Journal of infectious diseases.

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

C. Wheeler, H. Kitchener, M. Lehtinen, 2012, The Lancet. Oncology.

Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc analysis from a randomized controlled trial

M. Lehtinen, S. Garland, X. Castellsagué, 2016, International journal of cancer.

Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial.

H. Kitchener, M. Lehtinen, D. Harper, 2012, Gynecologic oncology.